EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors

Stephen T Sonis, Alessandro Villa iD

Cancers · 22.12.2023 · 16 (1) · 68

DOI: 10.3390/cancers16010068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 22.12.2023. Verfasst von Stephen T Sonis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Oral Medicine and Dentistry, Brigham and Women's Hospital and the Dana-Farber Cancer Institute, Boston, MA 02115, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It has been 24 years since rapamycin (sirolimus) was approved to mitigate solid organ transplant rejection and 16 years since mTOR (mammalian/mechanistic target of rapamycin) inhibitors reached patients as a cancer therapy. While the clinical benefits of mTOR inhibitors (mTORi) are robust, so too are their toxicities. Among the most common issues is the development of ulcers of the oral mucosa (mTOR-inhibitor associated stomatitis; mIAS). These lesions are distinct from those of other anti-cancer agents, occur with regularity, and impact patient outcomes. mIAS’ pathogenesis has been the subject of speculation, and its similar presentation to recurrent aphthous stomatitis (RAS) has led to the hypothesis that it might serve as a surrogate to better understand RAS. Based on a review of the literature, the current manuscript provides a hypothesis regarding the mechanisms by which mTORis uniquely initiate mucosal injury and an explanation for the observation that steroids (also an immunosuppressive) are effective in its treatment through a non-immunologic mechanism. Unexplained unique features of mIAS are discussed in this review in the context of future investigation.

Schlagwörter

Stichwörter der Autor:innen

aphthouscancereverolimusmTOR inhibitororal ulcerationrapamycin

Autor:innen und Institutionen

  • Divisions of Oral Medicine and Dentistry, Brigham and Women's Hospital and the Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA 02114, USA.
  • Biomodels, LLC, Waltham, MA 02451, USA.
  • Oral Medicine, Oral Oncology and Dentistry, Miami Cancer Institute, Miami, FL 33176, USA.
  • Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.

ORCID-Profile: Alessandro Villa

Zitieren

APA

Sonis, S. T., & Villa, A. (2023). A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors. Cancers, 16(1), 68. https://doi.org/10.3390/cancers16010068

Vancouver

Sonis ST, Villa A. A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors. Cancers. 2023;16(1):68. doi:10.3390/cancers16010068

BibTeX
@article{Sonis2023,
  author = {Sonis, Stephen T and Villa, Alessandro},
  title = {A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors},
  journal = {Cancers},
  year = {2023},
  volume = {16},
  number = {1},
  pages = {68},
  doi = {10.3390/cancers16010068}
}
Kostenlos starten →